Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 2, 2003, Pages 111-114

  Riccioni, G ^a   Della Vecchia, R ^a   D'Orazio, N ^a   Sensi, S ^a   Guagnano, M T ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Asthma; Bronchial hyperresponsiveness; Budesonide; Montelukast

Indexed keywords

ANTIASTHMATIC AGENT; BUDESONIDE; CORTICOSTEROID; MONTELUKAST;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0037350379     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(03)00002-6     Document Type: Article

References (27)

1. Global Initiative for Asthma: global strategy for asthma management and prevention. Global Initiative for Asthma: global strategy for asthma management and prevention. 1995;National Hearth, Lung and Blood Institute, National Institutes of Health, Bethesda, MD. Publication no 95-3659.
2. Booth H.I., Richmond I., Ward C., Gardiner P.V., Harkawat R., Walters E.H. Effect of high dose of inhaled fluticasone propionate on airway inflammation in asthma. J Clin Endocrinol Metab. 80:1995;1243-1246.
3. Olivieri D., Chetta A., Del Donno D., Bertorelli G., Casalini A., Pesci A., Testi R., Foresi A. Effect of short-term treatment with inhaled corticosteroids and/or beta-2 agonists on lung function, airway remodelling and symptoms in children with asthma: The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis. 146:1992;547-554.
4. Global Initiative for Asthma Management and Prevention (GINA). 1998;National Institute of Health. Publication no 96-3659B.
5. Kelloway J.S., Wyatt R.A., Adlis S.K. Comparison of patient's compliance with prescribed oral and inhaled asthma medication. Arch Intern Med. 154:1994;1349-1352.
6. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report II. 1997;National Hearth, Lung and Blood Institute - National Institutes of Health, Bethesda, MD. Publication No. 97-4051.
7. Coutts J.A., Gibson N.A. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 67:1992;332-333.
8. Armitage J.M., Williams S.J. Inhaled technique in the elderly. Age ageing. 17:1998;275-278.
9. Rand C.S., Wise R.A., Nides M., Simmonds M.S., Bleecker E.R., Kusek J.W., Li V.C., Tashkin D.P. Metered dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 146:1992;1559-1564.
10. Wilson A.M., Dempsey O.J., Simd E.J., Lipwort B.J. Evaluation of salmeterol or motelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest. 119:2001;1021-1026.
11. Jones T.R., Labelle M., Belley M., Champion E., Charette L., Evans J., Ford-Hucthinson A.W., Gauthier J.Y., Lord A., Masson P., McAuliffe M., McFarlane C.S., Metters K.M., Pickjett C., Piechuta H., Rodger I.W., Sawywe N., Young R.N., Zamboni R., Abraham W.M. Pharmacology of montelukast sodium (Singulair), a potent selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 73:1995;191-201.
12. Altman L.C., Munk Z., Seltzer J., Noonan S., Shingo S., Zhang J., Reiss T.F. The Montelukast Asthma Study Group. A placebo-controlled, dose ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol. 102:1998;50-56.
13. Guidelines for methacholine and exercise challenge testing. Am J Respir Crit Care Med. 161:2000;309-329.
14. Standardization of spirometry. Am J Respir Crit Care Med. 152:1995;1107-1136.
15. Laviolette M., Malmstrom K., Lu S., Chervinsky P., Pujet J.C., Peszek I., Zhang J., Reiss T.F. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 160:1999;1862-1868.
16. Lofdahl C.G., Reiss T.F., Leff J.A., Israel E., Noonan M.J., Finn A.F., Seidenberg B.C., Capizzi T., Kundu S., Godard P. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 319:1999;87-90.
17. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Pineiro A., Wei L.X., Seidenberg B.C., Reiss T.F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 130:1999;487-495.
18. Leff J.A., Busse W.W., Pearlman D., Bronsky E.A., Kemp J., Hendeles L., Dockhorn R., Kundu S., Zhang J., Seidenberg B.C., Reiss T.F. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 339:1998;147-152.
19. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., Edwards T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 158:1998;1213-1220.
20. Spector S. Non-compliance with asthma therapy - are there solutions? Allergy. 55:2000;740-748.
21. Clark N., Jones P., Keller S., Vermeire P. Patient factor and compliance with asthma therapy. Pediatr Pulmonol. 29:2000;46-61.
22. O'Shaughnessy K.M., Wellings R., Gillies B., Fuller R.W. Differential effect of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis. 147:1993;1472-1478.
23. Dworski R., Fitzgerelad G.A., Oates J.A., Sheller J.R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 149:1994;953-958.
24. Hood P.P., Cotter T.P., Costello J.F., Sampson A.P. Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax. 54:1999;1075-1082.
25. Dempsey O.J., Wilson A.M., Sims E.J., Mistry C., Lipworth B.J. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest. 117:2000;950-953.
26. Vignola A.M., Kips J., Bousquet J. Tissue remodelling as a feature of persistent asthma. J Allergy Clin Immunol. 105:2000;1041-1053.
27. Holgate S.T., Davies D.E., Lackie P.M., Wilson S.J., Puddicombe S.M., Lordan J.L. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol. 105:2000;193-204.